BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28540777)

  • 1. Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy.
    Sin EI; Chia CS; Tan GHC; Soo KC; Teo MC
    Int J Hyperthermia; 2017 Sep; 33(6):690-695. PubMed ID: 28540777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study.
    Ye J; Ren Y; Wei Z; Peng J; Chen C; Song W; Tan M; He Y; Yuan Y
    Surg Oncol; 2018 Sep; 27(3):456-461. PubMed ID: 30217302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors of chronic kidney disease in cisplatin-based hyperthermia intraperitoneal chemotherapy.
    Cheng CC; Yeh HC; Su PW; Ho CL; Chang SC
    Int J Hyperthermia; 2024; 41(1):2304250. PubMed ID: 38342495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeat Cytoreductive Surgery and HIPEC for Peritoneal Surface Malignancy and Peritoneal Carcinomatosis.
    Wong JF; Tan GH; Wang W; Soo KC; Teo MC
    World J Surg; 2015 Jun; 39(6):1578-83. PubMed ID: 25651962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management of recurrent/relapsed ovarian granulosa cell tumor: a single-center experience.
    Al-Badawi IA; Abu-Zaid A; Azzam A; AlOmar O; AlHusaini H; Amin T
    J Obstet Gynaecol Res; 2014 Sep; 40(9):2066-75. PubMed ID: 25181627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery.
    Hakeam HA; Breakiet M; Azzam A; Nadeem A; Amin T
    Ren Fail; 2014 Nov; 36(10):1486-91. PubMed ID: 25155314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
    Muñoz-Casares FC; Medina-Fernández FJ; Arjona-Sánchez Á; Casado-Adam Á; Sánchez-Hidalgo JM; Rubio MJ; Ortega-Salas R; Muñoz-Villanueva MC; Rufián-Peña S; Briceño FJ
    Eur J Surg Oncol; 2016 Feb; 42(2):224-33. PubMed ID: 26673283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
    Tan GH; Ong WS; Chia CS; Tham CK; Soo KC; Teo MC
    Int J Hyperthermia; 2016 May; 32(3):281-8. PubMed ID: 26862667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic intraperitonal chemotherapy is an independent risk factor for development of acute kidney injury.
    Dagel T; Misirlioglu S; Tanju S; Afsar B; Selcukbiricik F; Erus S; Vatansever D; Balik E; Taskiran C; Dilege S; Molinas Mandel N; Bugra D; Yalti T; Kanbay M
    J BUON; 2018; 23(5):1528-1533. PubMed ID: 30570881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with lobaplatin and docetaxel improves survival for patients with peritoneal carcinomatosis from abdominal and pelvic malignancies.
    Wu HT; Yang XJ; Huang CQ; Sun JH; Ji ZH; Peng KW; Zhang Q; Li Y
    World J Surg Oncol; 2016 Sep; 14(1):246. PubMed ID: 27633880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach.
    Hayes-Jordan A; Lopez C; Green HL; Xiao LC; Huh W; Herzog CE
    Pediatr Surg Int; 2016 Jan; 32(1):71-3. PubMed ID: 26500075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors of acute renal impairment after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chen CY; Chang HY; Lu CH; Chen MC; Huang TH; Lee LW; Liao YS; Chen VC; Huang WS; Ou YC; Lung FC; Wang TY
    Int J Hyperthermia; 2020; 37(1):1279-1286. PubMed ID: 33198563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
    van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
    Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.